Favorable course of peripartum cardiomyopathy (RCD code: VII-III-5C)

Paweł Rubiś, Mateusz Podolec, Sylwia Wiśniowska-Śmiałek, Wojciech Płazak, Jakub Stępniewski, Agata Leśniak-Sobelga, Jadwiga Nessler, Piotr Podolec

Full Text:

PDF

Abstract


Peripartum cardiomyopathy (PPCM) is defined as an idiopathic cardiomyopathy, presenting with heart failure (HF) secondary to left ventricular systolic dysfunction (LVSD) at the end of pregnancy or in the early months after delivery. Importantly, there should be no other identifiable cause of HF. The pathophysiology of PPCM is not fully understood and is probably multifactional. The data on the PPCM prognosis are sparse. Though initial reports suggested that mortality in PPCM vary geographically. We present a case of a a nulliparous 25-year-old Caucasian woman, who gradually developed dyspnea on exertion and fatigue 2 months after successful vaginal twin deliv- ery. She did not have any typical risk factors for cardiovascular diseases, her family history was unremarkable, and the whole pregnancy period was uneventful. After initiation of anti-HF therapy her clinical status gradually improved and she was discharged home with only mild symptoms and improved LV systolic function. JRCD 2015; 2 (3): 85–88


Keywords


cor triatriatum, congenital heart malformation

References


Silwa K, Hilfiker-Kleiner D, Petrie M, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767–778.

Fett JD, Christie LG, Carraway RD, Myrphy JG. Five year prospective study of the incidence and prognosis of peripartum cardiomyopathy at the single institution. Mayo Clin Proc 2005; 80: 1602–1606.

Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006; 97: 1765–1768.

Witlin AG, Mabie WC, Sibai BM. Peripartum cardiopyopathy: an omnious diagnosis. Am J Obstet Gynecol 1997; 176 (1 Pt 1): 182-188.

Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368: 687–693.

Chapa JB, Heiberger HB, Weinert L, et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005; 105: 1303–1308.

Duran N, Gunes H, Duran I, et al. Predictors of prognosis in patinets with peripartum cardiomyopathy. Int J Gynecol Obstet 2008; 101: 137–140.

Webb AJ, Thomsen HS, Morcos SK. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005; 15: 1234–1240.

Dickstein K, Cohen-Solal A, Fillipatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the ESC. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933–989.

Schaefer C. Angiotensin II-receptor-antagonists: further evidencof fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003; 67: 591–594.

Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443–2451.

Ghuman N, Rheiner J, Tendler BE, White WB. Hypertension in the postpartum woman: clinical update for the hypertension specialist. J Clin Hypertens (Greenwich) 2009; 11: 726–733.

Mioli M, Valenzano M, Bentivoglio G, Ferrero S. Peripartum cardiomyopathy. Arch Gynecol Obstet 2009; 281: 183–188.




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol2no3.163

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl